The 2017 North Carolina STOP Act is Associated With an Accelerated Decrease in Opioid Dispensing: A Statewide Analysis, 2013-2019.

Q2 Medicine
Chris Gillette, Amber K Brooks, Gayle B Bodner, Courtney J Perry
{"title":"The 2017 North Carolina STOP Act is Associated With an Accelerated Decrease in Opioid Dispensing: A Statewide Analysis, 2013-2019.","authors":"Chris Gillette, Amber K Brooks, Gayle B Bodner, Courtney J Perry","doi":"10.18043/001c.84335","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>This study aimed to: 1) quantify the dispensing and days' supply of opioid prescriptions prior to and after the NC STOP Act went into effect among Medicare Part D beneficiaries; 2) evaluate how the STOP Act impacted physician assistant and nurse practitioner opioid prescribing; and 3) evaluate whether the NC STOP Act is associated with reductions in opioid prescriptions' days' supply among Medicare Part D beneficiaries.</p><p><strong>Methods: </strong>This was a secondary analysis of Medicare Part D Public Use Files for 2013-2019. Only North Carolina providers and select Schedule II (CII) and III (CIII) drugs and tramadol (CV) were included in the analysis. Multivariable Poisson regression models were used to analyze the data.</p><p><strong>Results: </strong>In 2013, there were population-adjusted 180,565.2/100,000 claims for the included CII and CIII opioids, which decreased to 79,329.12/100,000 claims in 2019. Each of the multivariable Poisson regression models indicates a reduction in per-provider populationadjusted claims and days' supply after the NC STOP Act went into effect for both selected CII and CIII medications and for tramadol. The results also indicate that the number of prescriptions for CII, CIII, and tramadol decreased over time.</p><p><strong>Limitations: </strong>Due to the nature of the observational study design, we cannot conclude that the 2017 legislation had an effect on populationadjusted claims for certain CII and CIII opioids.</p><p><strong>Conclusions: </strong>Since 2013 there has been a decreasing trend in certain CII and CIII opioids dispensations in Medicare beneficiaries, and the trend accelerated after the STOP Act went into effect.</p>","PeriodicalId":39574,"journal":{"name":"North Carolina Medical Journal","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"North Carolina Medical Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18043/001c.84335","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Background: This study aimed to: 1) quantify the dispensing and days' supply of opioid prescriptions prior to and after the NC STOP Act went into effect among Medicare Part D beneficiaries; 2) evaluate how the STOP Act impacted physician assistant and nurse practitioner opioid prescribing; and 3) evaluate whether the NC STOP Act is associated with reductions in opioid prescriptions' days' supply among Medicare Part D beneficiaries.

Methods: This was a secondary analysis of Medicare Part D Public Use Files for 2013-2019. Only North Carolina providers and select Schedule II (CII) and III (CIII) drugs and tramadol (CV) were included in the analysis. Multivariable Poisson regression models were used to analyze the data.

Results: In 2013, there were population-adjusted 180,565.2/100,000 claims for the included CII and CIII opioids, which decreased to 79,329.12/100,000 claims in 2019. Each of the multivariable Poisson regression models indicates a reduction in per-provider populationadjusted claims and days' supply after the NC STOP Act went into effect for both selected CII and CIII medications and for tramadol. The results also indicate that the number of prescriptions for CII, CIII, and tramadol decreased over time.

Limitations: Due to the nature of the observational study design, we cannot conclude that the 2017 legislation had an effect on populationadjusted claims for certain CII and CIII opioids.

Conclusions: Since 2013 there has been a decreasing trend in certain CII and CIII opioids dispensations in Medicare beneficiaries, and the trend accelerated after the STOP Act went into effect.

2017年《北卡罗来纳州停止法案》与阿片类药物配药加速减少有关:2013-2019年全州分析
本研究旨在:1)量化《NC STOP法案》生效前后医疗保险D部分受益人的阿片类药物处方的配药和供应天数;2) 评估《停止法案》对医生助理和执业护士阿片类药物处方的影响;以及3)评估《NC STOP法案》是否与医疗保险D部分受益人阿片类药物处方“天数”供应的减少有关。这是对2013-2019年医疗保险D部分公共使用文件的二次分析。只有北卡罗来纳州的供应商和选定的附表II(CII)和III(CIII)药物以及曲马多(CV)被纳入分析。采用多变量泊松回归模型对数据进行分析。2013年,经人口调整的包括CII和CIII阿片类药物的索赔数量为1805652/100000,2019年降至79329.12/100000。每一个多变量泊松回归模型都表明,在选定的CII和CIII药物以及曲马多的NC STOP法案生效后,每个提供者经人群调整的索赔和天数减少。结果还表明,CII、CIII和曲马多的处方数量随着时间的推移而减少。由于观察性研究设计的性质,我们不能得出2017年立法对某些CII和CIII阿片类药物的人群调整索赔产生影响的结论。自2013年以来,联邦医疗保险受益人的某些CII和CIII阿片类药物处方呈下降趋势,《停止法案》生效后,这一趋势加速。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
North Carolina Medical Journal
North Carolina Medical Journal Medicine-Medicine (all)
CiteScore
1.40
自引率
0.00%
发文量
121
期刊介绍: NCMJ, the North Carolina Medical Journal, is meant to be read by everyone with an interest in improving the health of North Carolinians. We seek to make the Journal a sounding board for new ideas, new approaches, and new policies that will deliver high quality health care, support healthy choices, and maintain a healthy environment in our state.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信